|
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Clinical research trials and Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children. Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children clinical trial. Human subjects often get the best healthcare available for their Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children  Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
For Condition: untreated childhood supratentorial primitive neuroectodermal tumors,newly diagnosed childhood ependymoma,untreated childhood medulloblastoma,childhood choroid plexus tumor,childhood central nervous system germ cell tumor
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Pediatric Brain Tumor Consortium
Synopsis: RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to learn more about genes involved in the development of central nervous system tumors in young children.
Details: OBJECTIVES: I. Identify known genes that have significantly different levels of expression, using microarray gene chip analysis, in infants with newly diagnosed metastatic vs non-metastatic embryonal central nervous system tumors. II. Determine the protein expression of genes identified by microarray analysis that are involved in cellular functions that regulate angiogenesis, invasion, or metastasis in this patient population. III. Determine the quantity of gene expression of the confirmed translationally expressed genes using semi-quantitative polymerase chain reaction. PROTOCOL OUTLINE: This is a multicenter study. Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed genes are evaluated for protein expression by standard immunohistochemistry and/or Western blot analysis, and gene expression is further quantified by semi-quantitative polymerase chain reaction. PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75 with non-metastatic disease) will be accrued for this study within 4-5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /2 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed, newly diagnosed, primary intracranial embryonal central nervous system tumor - Medulloblastoma - Primitive neuroectodermal tumor - Medulloepithelioma - Ependymoblastoma - Neuroblastoma - Pineoblastoma - Atypical teratoid/rhabdoid tumor - Intracranial germ cell tumor - Choroid plexus carcinoma - M positive ependymoma Potential enrollment on PBTC-001 therapeutic protocol --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy - Endocrine therapy: Prior steroids allowed - Radiotherapy: No prior radiotherapy - Surgery: Not specified - Other: No concurrent investigational agents --Patient Characteristics-- - Age: Under 3 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
TobeyMacDonald, Study Chair, Pediatric Brain Tumor Consortium
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105-2794
United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970
United States
Additional Information:
Study ID Numbers: CDR0000068446; PBTC-N04
Study Start Date: March 2001
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00010114
Other Childhood Choroid Plexus Tumor Studies:
1. Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
2. Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
3. Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors
4. Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
5. Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
Related Studies:
Other childhood choroid plexus tumor Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
|
|
|
|
|
|
|
|
